Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Carotid Artery Diseases

ClinicalTrials.gov lists 604 trials for Carotid Artery Diseases or a narrower condition beneath it. National Heart, Lung, and Blood Institute (NHLBI) has the most among industry and government lead sponsors, with 16.

MeSH D002340 Nervous System Diseases C10 C14
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 14 Phase 1/2 Phase 1/2 5 Phase 2 Phase 2 32 Phase 2/3 Phase 2/3 4 Phase 3 Phase 3 30 Phase 4 Phase 4 32 Not applicable Not applicable 196 Observational Observational 290 Phase 1 Phase 1 14 Phase 1/2 Phase 1/2 5 Phase 2 Phase 2 32 Phase 2/3 Phase 2/3 4 Phase 3 Phase 3 30 Phase 4 Phase 4 32 Not applicable Not applicable 196 Observational Observational 290

Trials per phase (log scale)

1 more section with rows

254 of the 604 trials are tagged with Carotid Artery Diseases itself; the rest are tagged with a narrower condition beneath it.

Get the Carotid Artery Diseases report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Carotid Artery Diseases trials start? (36)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 41

1990: 3 trials (Observational 3) 1991: 1 trials (Observational 1) 1992: 1 trials (Observational 1) 1993: 1 trials (Phase 1 1) 1994: 2 trials (Observational 2) 1995: 3 trials (Observational 1, Not applicable 1, Phase 2 1) 1996: 2 trials (Observational 2) 1997: 2 trials (Observational 2) 1998: 1 trials (Observational 1) 2000: 7 trials (Observational 2, Not applicable 1, Phase 3 3, Phase 2/3 1) 2001: 4 trials (Observational 2, Not applicable 1, Phase 4 1) 2002: 4 trials (Observational 1, Not applicable 2, Phase 4 1) 2003: 11 trials (Observational 6, Not applicable 2, Phase 4 1, Phase 3 1, Phase 2 1) 2004: 8 trials (Observational 1, Not applicable 3, Phase 3 4) 2005: 11 trials (Observational 4, Not applicable 2, Phase 4 1, Phase 3 3, Phase 2 1) 2006: 20 trials (Observational 9, Not applicable 5, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 1, Phase 1 2) 2007: 16 trials (Observational 8, Not applicable 5, Phase 4 1, Phase 2 2) 2008: 13 trials (Observational 2, Not applicable 7, Phase 4 2, Phase 2 1, Phase 1/2 1) 2009: 15 trials (Observational 3, Not applicable 5, Phase 4 2, Phase 3 2, Phase 2 3) 2010: 17 trials (Observational 7, Not applicable 5, Phase 4 2, Phase 3 1, Phase 2/3 1, Phase 1/2 1) 2011: 23 trials (Observational 12, Not applicable 7, Phase 4 1, Phase 3 2, Phase 2 1) 2012: 29 trials (Observational 18, Not applicable 5, Phase 3 2, Phase 2 2, Phase 1/2 1, Phase 1 1) 2013: 18 trials (Observational 8, Not applicable 7, Phase 2 2, Phase 1 1) 2014: 20 trials (Observational 12, Not applicable 6, Phase 4 1, Phase 3 1) 2015: 22 trials (Observational 9, Not applicable 8, Phase 4 2, Phase 3 1, Phase 2 1, Phase 1 1) 2016: 23 trials (Observational 4, Not applicable 15, Phase 4 2, Phase 2 2) 2017: 30 trials (Observational 12, Not applicable 9, Phase 4 4, Phase 3 1, Phase 2 4) 2018: 25 trials (Observational 10, Not applicable 10, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 2) 2019: 32 trials (Observational 17, Not applicable 12, Phase 4 1, Phase 2 1, Phase 1 1) 2020: 22 trials (Observational 14, Not applicable 4, Phase 4 2, Phase 3 1, Phase 1 1) 2021: 36 trials (Observational 25, Not applicable 7, Phase 4 2, Phase 3 1, Phase 2 1) 2022: 41 trials (Observational 28, Not applicable 11, Phase 3 1, Phase 1 1) 2023: 33 trials (Observational 20, Not applicable 10, Phase 3 1, Phase 1/2 1, Phase 1 1) 2024: 31 trials (Observational 11, Not applicable 16, Phase 4 1, Phase 2 2, Phase 1 1) 2025: 34 trials (Observational 14, Not applicable 15, Phase 3 1, Phase 2 2, Phase 1 2)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 31
2025 34
2024 31
2023 33
2022 41
2021 36
2020 22
2019 32
2018 25
2017 30

Showing 10 of 36 earlier years.

Start your 14-day trial Email me all 36 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 38 trials starting in 2026 and about 34 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 35 trials still running at the 2026-10-09 snapshot; registered median of 31 months across 287 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Carotid Artery Diseases trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 14
Phase 1/2 5
Phase 2 32
Phase 2/3 4
Phase 3 30
Phase 4 32
Not applicable 196
Observational 290
Expanded access 1

How many Carotid Artery Diseases trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 30
Recruiting 86
Enrolling by invitation 6
Active, not recruiting 18
Completed 259

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Carotid Artery Diseases trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 16
Silk Road Medical 9
Abbott Medical Devices 8
Boston Scientific Corporation 6

Which drugs are being tested for Carotid Artery Diseases? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
ATORVASTATIN 9
ROSUVASTATIN 3
SIMVASTATIN 3

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
EC Aspirin 8
Clopidogrel 75 6
MRI 4
No Interventions 3
ER Niacin 3

Showing 5 of 12 interventions.

Start your 14-day trial Email me all 12 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Carotid Artery Diseases trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Hypotension 350 12
Vascular Disorders 268 1
Neurologic SAE 191 1
Nervous System Disorders 142 1
Hemodynamic SAE 129 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Carotid Artery Diseases? (632)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Differentiation of Atherosclerotic Carotid Plaque Components With Dual-Energy Computed Tomography. Investigative radiology 2025 Yes
Current Therapy for Carotid Webs. Annals of vascular surgery 2025 Yes
Carotid Plaque-Burden scale and outcomes: A real-life study. Medicina clinica 2025 Yes
Textbook outcomes as a novel patient-centric metric to inform carotid revascularization. Journal of vascular surgery 2025 Yes
Associations of subclinical microcalcification and inflammation with carotid atheroma development: a dual-tracer PET/CT study. European journal of nuclear medicine and molecular imaging 2025 Yes

Showing 5 of 632 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (6)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages